Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ortin GlobalBOM:539287 43 3-Year ROIIC % is 6.67 as of Mar. 2026, which is 6% above its 10-year median of 6.30. GuruFocus rates BOM:539287 with a GF Score™ of 43/100 and a GF Value™ of ₹1.98 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 944 Drug Manufacturers companies, Ortin Global ranks better than 55.08% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Ortin Global's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 6.67%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Ortin Global's 3-Year ROIIC % or its related term are showing as below:
BOM:539287's 3-Year ROIIC % is ranked better than 55.08% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.61
vs BOM:539287: 6.67
Ortin Global (BOM:539287) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Ortin Global 3-Year ROIIC % Related Terms
Ortin Global 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Ortin Global's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Global's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortin Global 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ortin Global's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Ortin Global's 3-Year ROIIC % falls into.
Ortin Global's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -7.212 (Mar. 2026) - 2.2922526 (Mar. 2023) )
/
( 40.029 (Mar. 2026) - 182.455 (Mar. 2023) )
=
-9.5042526
/
-142.426
=
6.67%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Ortin Global (BOM:539287) has a 3-Year ROIIC % of 6.67 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ortin Global and its competitors. This is near median its historical median of 6.30. According to the industry distribution chart, Ortin Global ranks #424 out of 944 companies in the Drug Manufacturers industry, placing it in the top 44.9%.
Is Ortin Global's 3-Year ROIIC % too high?
Ortin Global's current 3-Year ROIIC % of 6.67 is near median its 10-year median of 6.30. The Drug Manufacturers industry median 3-Year ROIIC % is 3.61. Ortin Global's value of 6.67 is 84.8% above this industry median. Based on the distribution chart, Ortin Global ranks #424 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ortin Global has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ortin Global's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ortin Global ranks #424 out of 944 companies for 3-Year ROIIC %. This puts Ortin Global in the upper half of its industry. The industry median 3-Year ROIIC % is 3.61. Ortin Global's value of 6.67 is 84.8% above this benchmark. While the company's 10-year median is 6.30 vs. the industry median of 3.61, Ortin Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.61, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ortin Global's current 3-Year ROIIC % of 6.67 is 84.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ortin Global and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortin Global's current 3-Year ROIIC % is 6.67, which is near median its own 10-year median of 6.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortin Global stock overvalued right now?
Based on GuruFocus' analysis, Ortin Global (BOM:539287) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1.98, compared to a current price of ₹15.19 — trading 667.2% above its estimated fair value. The current 3-Year ROIIC % is 6.67, which is near median its 10-year median of 6.30 and 84.8% above the Drug Manufacturers industry median of 3.61. Ortin Global's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Ortin Global (BOM:539287), the current 3-Year ROIIC % is 6.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortin Global (BOM:539287) Overvalued in 2026?
Based on GuruFocus' analysis, Ortin Global stock appears to be overvalued.
The current stock price of ₹15.19 is trading 667.2% above its estimated GF Value™ of ₹1.98.
GuruFocus considers Ortin Global to be Significantly Overvalued.
Key valuation signals for BOM:539287:
3-Year ROIIC %: 6.67 (near median its 10-year median of 6.30)
GF Value™: ₹1.98 vs. price of ₹15.19 (667.2% above fair value)
Industry Position: 84.8% above the Drug Manufacturers median (#424 of 944)
No single metric tells the full story. See the BOM:539287 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortin Global Ltd is an Indian company engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helminthics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its API intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zidovudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others. Additionally, the company is also involved in the real estate business.
43GF Score
Get the complete analysis for BOM:539287
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539287 has been successfully added to your 
